Transcripta Bio Lands $24 Million Series A

<p><strong>PALO ALTO<&sol;strong> &&num;8212&semi; <a href&equals;"https&colon;&sol;&sol;cts&period;businesswire&period;com&sol;ct&sol;CT&quest;id&equals;smartlink&amp&semi;url&equals;https&percnt;3A&percnt;2F&percnt;2Fwww&period;transcriptabio&period;com&percnt;2F&amp&semi;esheet&equals;54574854&amp&semi;newsitemid&equals;20260721361541&amp&semi;lan&equals;en-US&amp&semi;anchor&equals;Transcripta&plus;Bio&amp&semi;index&equals;1&amp&semi;md5&equals;0359fa673b705315668789c314b1a9f9" target&equals;"&lowbar;blank" rel&equals;"nofollow noopener" shape&equals;"rect">Transcripta Bio<&sol;a>&comma; an AI-powered drug discovery company focused on neurological and neuromuscular diseases&comma; has raised &dollar;24 million since its Series A to advance IND-enabling studies across its portfolio and support clinical preparation in its Autism Spectrum Disorder &lpar;ASD&rpar; and Facioscapulohumeral Muscular Dystrophy &lpar;FSHD&rpar; programs&period; Mayo Clinic and Omnimed join existing investors JAZZ Venture Partners&comma; BlueYard Capital&comma; and a group of life sciences family offices as the company advances its pipeline toward human clinical trials&period; The company&&num;8217&semi;s pipeline spans four programs across Myotonic Dystrophy&comma; FSHD&comma; ASD&comma; and Huntington&&num;8217&semi;s Disease &lpar;HD&rpar;&period;<&sol;p>&NewLine;<p>Transcripta Bio&&num;8217&semi;s closed-loop discovery engine is designed to use transcriptomic signature matching to identify drugs whose molecular signatures are the inverse of patient-derived disease signatures&period; The platform combines a Disease Signature Atlas built from actual patient single-cell RNA sequencing data&comma; a Drug-Gene Atlas mapping the full transcriptomic response of FDA-approved and novel compounds&comma; and Conductor AI&comma; a machine learning system trained on more than one billion gene responses that begins at lead optimization rather than hit identification&period; Together&comma; these three components systematically assess compounds&comma; with the goal of de-risking drug development by addressing the root causes of clinical failure before candidates ever reach the clinic&period;<&sol;p>&NewLine;<p>&&num;8220&semi;Transcripta was founded to address the failure points that keep drugs from reaching the clinic&period; Our platform has already demonstrated results and this capital accelerates that work for diseases that have waited long enough for real treatments&comma;&&num;8221&semi; said Chris Moxham&comma; founder and CEO&comma; Transcripta Bio&period; &&num;8220&semi;Transcripta Bio is positioned to demonstrate what AI-native drug discovery can deliver for patients with neurological and neuromuscular diseases&period;&&num;8221&semi;<&sol;p>&NewLine;<p>&&num;8220&semi;Transcripta Bio has developed a discovery platform grounded in patient biology and applied it across four programs with significant unmet need&comma;&&num;8221&semi; said Greg Wood&comma; Managing Director&comma; Omnimed&period; &&num;8220&semi;We look forward to seeing what they can accomplish moving forward&period;&&num;8221&semi;<&sol;p>&NewLine;